Description
AMG 355 is an investigational medication being studied by Amgen for various advanced solid tumors, including colorectal cancer. It is currently in Phase 1 clinical trials. These early-stage trials primarily focus on determining the safety and tolerability of the drug, both when given alone (as monotherapy) and in combination with another immunotherapy drug called pembrolizumab. Researchers are also working to find the right dose of AMG 355 that can be used safely in future studies. The goal is to see if AMG 355 can help patients with advanced cancers, potentially by working together with drugs like pembrolizumab.
Mechanism of Action
AMG 355 is being investigated as a potential treatment for advanced solid tumors. The specific way it works (its mechanism of action) is still being studied in clinical trials. Researchers are evaluating how it affects cancer cells and interacts with the immune system, particularly when combined with other therapies like pembrolizumab.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.